Phase 1b Open-Label Trial of Afatinib Plus Xentuzumab (BI 836845) in Patients With EGFR Mutation-Positive NSCLC After Progression on EGFR Tyrosine Kinase Inhibitors

Park K.Tan D.S.W.Su W.-C.Cho B.C.Kim S.-W.Lee K.H.Wang C.-C.Seto T.Huang D.C.-L.Jung H.H.Hsu M.-C.Bogenrieder T.CHIA-CHI LIN2022-09-152022-09-1520212666-3643https://www.scopus.com/inward/record.uri?eid=2-s2.0-85122741646&doi=10.1016%2fj.jtocrr.2021.100206&partnerID=40&md5=8538b6bbe9ff63701f22e2c3e48f0595https://scholars.lib.ntu.edu.tw/handle/123456789/620212Phase 1b Open-Label Trial of Afatinib Plus Xentuzumab (BI 836845) in Patients With EGFR Mutation-Positive NSCLC After Progression on EGFR Tyrosine Kinase Inhibitorsjournal article10.1016/j.jtocrr.2021.1002062-s2.0-85122741646